Last reviewed 2026-04-20 · How we verify

MHB039A

Minghui Pharmaceutical (Hangzhou) Ltd · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	MHB039A
Sponsor	Minghui Pharmaceutical (Hangzhou) Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MHB039A for Advanced Solid Tumor (PHASE1, PHASE2)
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors (PHASE1, PHASE2)
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors (PHASE2)
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results